NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
ZIPHIUS
ST13
US500000079366407Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Andrea S. Fuelleman Neal, Gerber & Eisenberg LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders, infectious diseases, parasitic diseases, and oncology in the field of cystic Fibrosis, chlamydia trachomatis, eppstein barr, herpes zoster, herpes simplex, coronaviruses, malaria, leishmaniasis, and trypanosomiasis; chikungunya, dengue, lymphatic filariasis, rift valley fever, yellow fever, zika, malaria, Japanese encephalitis, West Nile fever, schistosomiasis (bilharziasis), Onchocerciasis (river blindness), plagues, tungiasis, typhus, louse-borne relapsing fever, Leishmaniasis, Sandfly fever (Phlebotomus fever), Crimean Congo haemorrhagic fever, Lyme disease, Relapsing fever (borreliosis), rickettsial diseases, Tick-borne encephalitis, tularaemia, chagas disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), all of the foregoing based on self-amplifying RNA and Lipid based delivery vehicles; vaccines
Classe 9
Downloadable mobile applications and downloadable computer software to enable healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; Downloadable e-commerce software to enable users to perform electronic business transactions via a global computer network; Downloadable computer software to enable professionals to optimize workflow, capture and organize information, place orders and track expenses
Classe 10
Surgical apparatus and instruments for medical use; blood pressure and diabetic diagnostic medical devices
Classe 35
Provision of information and advisory services relating to electronic commerce; provision of customer information on pharmaceutical and medical products through an on-line computer network for advertising purposes
Classe 42
Scientific research for medical purposes
Classe 44
Medical services and healthcare services namely, offered through a network of healthcare providers on a contract basis; provision of medical information; provision of medical information to patients and healthcare professionals concerning pharmaceutical products, vaccines, medical diseases and disorders and related treatments via the Internet; gene therapy and stem cell therapy services; medical and psychological counselling services; medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
NEW REPRESENTATIVE AT IB RECEIVED
13/11/2025
FINAL DECISION TRANSACTION PROCESSED BY IB
08/03/2025
FINAL DISPOSITION NOTICE SENT TO IB
18/02/2025
FINAL DISPOSITION PROCESSED
18/02/2025
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/12/2024
CHANGE OF NAME/ADDRESS REC'D FROM IB
28/09/2024
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
14/09/2024
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/09/2024
REGISTERED-PRINCIPAL REGISTER
03/09/2024
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/08/2024
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
28/08/2024
NOTIFICATION PROCESSED BY IB
01/07/2024
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/06/2024
PUBLISHED FOR OPPOSITION
18/06/2024
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/06/2024
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/06/2024
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/05/2024
APPROVED FOR PUB - PRINCIPAL REGISTER
16/05/2024
TEAS/EMAIL CORRESPONDENCE ENTERED
15/05/2024
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/05/2024
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/05/2024
REFUSAL PROCESSED BY IB
02/01/2024
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/12/2023
REFUSAL PROCESSED BY MPU
11/12/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/12/2023
NON-FINAL ACTION WRITTEN
07/12/2023
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
04/12/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/12/2023
NON-FINAL ACTION WRITTEN
02/12/2023
ASSIGNED TO EXAMINER
02/12/2023
APPLICATION FILING RECEIPT MAILED
07/04/2023
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/04/2023
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/03/2023
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.